163 related articles for article (PubMed ID: 33837880)
1. Synchronous brain metastases as a poor prognosis factor in clear cell renal carcinoma: a strong argument for systematic brain screening.
Ruste V; Sunyach MP; Tanguy R; Jouanneau E; Schiffler C; Carbonnaux M; Moriceau G; Neidhardt EM; Boyle H; Robin S; Négrier S; Fléchon A
J Neurooncol; 2021 May; 153(1):133-141. PubMed ID: 33837880
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma.
Choi SY; Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
Clin Genitourin Cancer; 2017 Dec; 15(6):717-723. PubMed ID: 28552571
[TBL] [Abstract][Full Text] [Related]
3. Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.
Ha FJ; Spain L; Dowling A; Kwan EM; Pezaro C; Day D; Chia PL; Tran B; Pook D; Weickhardt AJ
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e97-e102. PubMed ID: 30701671
[TBL] [Abstract][Full Text] [Related]
4. Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases.
Bowman IA; Bent A; Le T; Christie A; Wardak Z; Arriaga Y; Courtney K; Hammers H; Barnett S; Mickey B; Patel T; Whitworth T; Stojadinovic S; Hannan R; Nedzi L; Timmerman R; Brugarolas J
Clin Genitourin Cancer; 2019 Apr; 17(2):e263-e272. PubMed ID: 30538068
[TBL] [Abstract][Full Text] [Related]
5. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma.
Verma J; Jonasch E; Allen PK; Weinberg JS; Tannir N; Chang EL; Mahajan A
Am J Clin Oncol; 2013 Dec; 36(6):620-4. PubMed ID: 22892430
[TBL] [Abstract][Full Text] [Related]
6. Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases.
Parmar A; Soliman H; Sahgal A; Bjarnason GA
Clin Genitourin Cancer; 2020 Jun; 18(3):e224-e232. PubMed ID: 32139300
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.
Ruatta F; Derosa L; Escudier B; Colomba E; Guida A; Baciarello G; Loriot Y; Fizazi K; Albiges L
Eur J Cancer; 2019 Jan; 107():79-85. PubMed ID: 30551078
[TBL] [Abstract][Full Text] [Related]
8. Outcome and prognostic factors in single brain metastases from small-cell lung cancer.
Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hörner-Rieber J; König L; Kappes J; Thomas M; Unterberg A; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
Strahlenther Onkol; 2018 Feb; 194(2):98-106. PubMed ID: 29085978
[TBL] [Abstract][Full Text] [Related]
9. Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma.
Du Y; Pahernik S; Hadaschik B; Teber D; Duensing S; Jäger D; Hohenfellner M; Grüllich C
J Neurooncol; 2016 Oct; 130(1):221-228. PubMed ID: 27538910
[TBL] [Abstract][Full Text] [Related]
10. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC
Eur Urol Oncol; 2020 Aug; 3(4):530-539. PubMed ID: 32037304
[TBL] [Abstract][Full Text] [Related]
11. Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma.
Vogl UM; Bojic M; Lamm W; Frischer JM; Pichelmayer O; Kramer G; Haitel A; Kitz K; Harmankaya K; Zielinski CC; Schmidinger M
BMC Cancer; 2010 Sep; 10():480. PubMed ID: 20819239
[TBL] [Abstract][Full Text] [Related]
12. Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.
Haaker L; Tryssesoone L; Renders I; Verbiest A; Lerut E; Baldewijns M; Bourgain C; Roussel E; Van den Bulck H; Wynendaele W; Laguerre B; Rioux-Leclercq N; Oudard S; Laenen A; Debruyne PR; Albersen M; Beuselinck B
Urol Oncol; 2020 Aug; 38(8):686.e1-686.e9. PubMed ID: 32430250
[TBL] [Abstract][Full Text] [Related]
13. Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.
Sperduto PW; Deegan BJ; Li J; Jethwa KR; Brown PD; Lockney N; Beal K; Rana NG; Attia A; Tseng CL; Sahgal A; Shanley R; Sperduto WA; Lou E; Zahra A; Buatti JM; Yu JB; Chiang V; Molitoris JK; Masucci L; Roberge D; Shi DD; Shih HA; Olson A; Kirkpatrick JP; Braunstein S; Sneed P; Mehta MP
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):845-853. PubMed ID: 29976497
[TBL] [Abstract][Full Text] [Related]
14. An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study.
Internò V; Massari F; Rudà R; Maiorano BA; Caffo O; Procopio G; Bracarda S; Atzori F; Passarelli A; Bersanelli M; Stellato M; Fornarini G; Galli L; Ortega C; Zanardi E; Incorvaia L; Facchini G; Giron Berrios JR; Ricotta R; Santoni M; Funaioli C; Trerotoli P; Porta C; Rizzo M
ESMO Open; 2023 Aug; 8(4):101598. PubMed ID: 37467658
[TBL] [Abstract][Full Text] [Related]
15. Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery.
Stenman M; Benmakhlouf H; Wersäll P; Johnstone P; Hatiboglu MA; Mayer-da-Silva J; Harmenberg U; Lindskog M; Sinclair G
Acta Neurochir (Wien); 2021 Feb; 163(2):333-342. PubMed ID: 32902689
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma.
Wardak Z; Christie A; Bowman A; Stojadinovic S; Nedzi L; Barnett S; Patel T; Mickey B; Whitworth T; Hannan R; Brugarolas J; Timmerman R
Clin Genitourin Cancer; 2019 Apr; 17(2):e273-e280. PubMed ID: 30595522
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
